GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...
GSK shares top the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to ...
Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed ...
British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.
How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive ...
If you or a loved one took Zantac (ranitidine) and later developed health complications, particularly cancer, you may be ...
UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...
GSK declared a third-quarter dividend of 15.00 pence per share, unchanged from the second quarter, but up 7.1% from 14.00p per share last year. It continues to expect a total dividend of 60.00p per ...
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...
GSK has reached agreements with 10 plaintiff firms to settle around 80,000 state court product liability cases related to its heartburn medication, Zantac ... GSK agreed to pay $70 million ...
GSK (GSK.L), opens new tab shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac ...
Oct 9 (Reuters) - GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company ...